Your fact-checks will appear here
The FDA approval and effects of lecanemab and donanemab for early symptomatic Alzheimer's disease treatment.
Proven treatments for Alzheimer’s disease fall into two camps: modest symptomatic drugs that have been used for decades (cholinesterase inhibitors and memantine) and newer anti-amyloid immunotherapies...
Current ‑approved treatments for fall into two broad groups: long-standing symptom‑relief drugs (cholinesterase inhibitors and memantine) and newer disease‑modifying anti‑amyloid monoclonal antibodies...
Amyloid plaques—extracellular aggregates built largely from amyloid‑β (Aβ) peptides—are one of the two classic neuropathologic hallmarks used to define Alzheimer’s disease alongside intracellular tau ...